Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

NCT05382559 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT05382559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05382559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Recruiting
Start date
June 8, 2022
Completion date
December 31, 2028
Enrollment
681 (estimated)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor